<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:07:40Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8232441" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8232441</identifier>
        <datestamp>2021-07-07</datestamp>
        <setSpec>plosone</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" xml:lang="en" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">PLoS One</journal-id>
              <journal-id journal-id-type="iso-abbrev">PLoS One</journal-id>
              <journal-id journal-id-type="publisher-id">plos</journal-id>
              <journal-title-group>
                <journal-title>PLoS ONE</journal-title>
              </journal-title-group>
              <issn pub-type="epub">1932-6203</issn>
              <publisher>
                <publisher-name>Public Library of Science</publisher-name>
                <publisher-loc>San Francisco, CA USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8232441</article-id>
              <article-id pub-id-type="pmcid">PMC8232441</article-id>
              <article-id pub-id-type="pmc-uid">8232441</article-id>
              <article-id pub-id-type="pmid">34170908</article-id>
              <article-id pub-id-type="doi">10.1371/journal.pone.0253014</article-id>
              <article-id pub-id-type="publisher-id">PONE-D-20-35204</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Cardiology</subject>
                    <subj-group>
                      <subject>Heart Failure</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Pharmacology</subject>
                    <subj-group>
                      <subject>Drugs</subject>
                      <subj-group>
                        <subject>Diuretics</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Health Care</subject>
                    <subj-group>
                      <subject>Patients</subject>
                      <subj-group>
                        <subject>Outpatients</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Body Fluids</subject>
                      <subj-group>
                        <subject>Urine</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Anatomy</subject>
                    <subj-group>
                      <subject>Body Fluids</subject>
                      <subj-group>
                        <subject>Urine</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Physiology</subject>
                    <subj-group>
                      <subject>Body Fluids</subject>
                      <subj-group>
                        <subject>Urine</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Hematology</subject>
                    <subj-group>
                      <subject>Hemodynamics</subject>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Cardiology</subject>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Diagnostic Medicine</subject>
                    <subj-group>
                      <subject>Diagnostic Radiology</subject>
                      <subj-group>
                        <subject>Ultrasound Imaging</subject>
                        <subj-group>
                          <subject>Echocardiography</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Research and Analysis Methods</subject>
                  <subj-group>
                    <subject>Imaging Techniques</subject>
                    <subj-group>
                      <subject>Diagnostic Radiology</subject>
                      <subj-group>
                        <subject>Ultrasound Imaging</subject>
                        <subj-group>
                          <subject>Echocardiography</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Medicine and Health Sciences</subject>
                  <subj-group>
                    <subject>Radiology and Imaging</subject>
                    <subj-group>
                      <subject>Diagnostic Radiology</subject>
                      <subj-group>
                        <subject>Ultrasound Imaging</subject>
                        <subj-group>
                          <subject>Echocardiography</subject>
                        </subj-group>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="Discipline-v3">
                  <subject>Biology and Life Sciences</subject>
                  <subj-group>
                    <subject>Biochemistry</subject>
                    <subj-group>
                      <subject>Biomarkers</subject>
                      <subj-group>
                        <subject>Creatinine</subject>
                      </subj-group>
                    </subj-group>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>OUTpatient intravenous LASix Trial in reducing hospitalization for acute decompensated heart failure (OUTLAST)</article-title>
                <alt-title alt-title-type="running-head">Outpatient IV LASix in reducing HF hospitalization</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7063-1727</contrib-id>
                  <name>
                    <surname>Hamo</surname>
                    <given-names>Carine E.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Abdelmoneim</surname>
                    <given-names>Sahar S.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Formal analysis</role>
                  <role content-type="https://casrai.org/credit/">Writing – original draft</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Han</surname>
                    <given-names>Seol Young</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Chandy</surname>
                    <given-names>Elizabeth</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Muntean</surname>
                    <given-names>Cornelia</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Khan</surname>
                    <given-names>Saadat A.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sunkesula</surname>
                    <given-names>Prasanthi</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Meykler</surname>
                    <given-names>Marcella</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6011-0899</contrib-id>
                  <name>
                    <surname>Ramachandran</surname>
                    <given-names>Vidhya</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rosenberg</surname>
                    <given-names>Emelie</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Klem</surname>
                    <given-names>Igor</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff003" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sacchi</surname>
                    <given-names>Terrence J.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Heitner</surname>
                    <given-names>John F.</given-names>
                  </name>
                  <role content-type="https://casrai.org/credit/">Conceptualization</role>
                  <role content-type="https://casrai.org/credit/">Data curation</role>
                  <role content-type="https://casrai.org/credit/">Methodology</role>
                  <role content-type="https://casrai.org/credit/">Supervision</role>
                  <role content-type="https://casrai.org/credit/">Writing – review &amp; editing</role>
                  <xref rid="aff002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="cor001" ref-type="corresp">*</xref>
                </contrib>
              </contrib-group>
              <aff id="aff001">
                <label>1</label>
                <addr-line>Division of Cardiology, Johns Hopkins University, Baltimore, Maryland, United States of America</addr-line>
              </aff>
              <aff id="aff002">
                <label>2</label>
                <addr-line>Division of Cardiology, Brooklyn New York-Presbyterian Hospital, Brooklyn, New York, United States of America</addr-line>
              </aff>
              <aff id="aff003">
                <label>3</label>
                <addr-line>The Duke Clinical Research Institute, Durham, North Carolina, United States of America</addr-line>
              </aff>
              <contrib-group>
                <contrib contrib-type="editor">
                  <name>
                    <surname>Abdelbasset</surname>
                    <given-names>Walid Kamal</given-names>
                  </name>
                  <role>Editor</role>
                  <xref rid="edit1" ref-type="aff"/>
                </contrib>
              </contrib-group>
              <aff id="edit1">
                <addr-line>Prince Sattam Bin Abdulaziz University, College of Applied Medical Sciences, SAUDI ARABIA</addr-line>
              </aff>
              <author-notes>
                <fn fn-type="COI-statement" id="coi001">
                  <p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p>
                </fn>
                <corresp id="cor001">* E-mail: <email>jfh9003@nyp.org</email></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>25</day>
                <month>6</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <year>2021</year>
              </pub-date>
              <volume>16</volume>
              <issue>6</issue>
              <elocation-id>e0253014</elocation-id>
              <history>
                <date date-type="received">
                  <day>30</day>
                  <month>12</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>21</day>
                  <month>5</month>
                  <year>2021</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2021 Hamo et al</copyright-statement>
                <copyright-year>2021</copyright-year>
                <copyright-holder>Hamo et al</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="pone.0253014.pdf"/>
              <abstract>
                <sec id="sec001">
                  <title>Background</title>
                  <p>Hospitalization for acute decompensated heart failure (ADHF) remains a major source of morbidity and mortality. The current study aimed to investigate the feasibility, safety, and efficacy of outpatient furosemide intravenous (IV) infusion following hospitalization for ADHF.</p>
                </sec>
                <sec id="sec002">
                  <title>Methods</title>
                  <p>In a single center, prospective, randomized, double-blind study, 100 patients were randomized to receive standard of care (Group 1), IV placebo infusion (Group 2), or IV furosemide infusion (Group 3) over 3h, biweekly for a one-month period following ADHF hospitalization. Patients in Groups 2/3 also received a comprehensive HF-care protocol including bi-weekly clinic visits for dose-adjusted IV-diuretics, medication adjustment and education. Echocardiography, quality of life and depression questionnaires were performed at baseline and 30-day follow-up. The primary outcome was 30-day re-hospitalization for ADHF.</p>
                </sec>
                <sec id="sec003">
                  <title>Results</title>
                  <p>Overall, a total of 94 patients were included in the study (mean age 64 years, 56% males, 69% African American). There were a total of 14 (15%) hospitalizations for ADHF at 30 days, 6 (17.1%) in Group 1, 7 (22.6%) in Group 2, and 1 (3.7%) in Group 3 (overall p = 0.11; p = 0.037 comparing Groups 2 and 3). Patients receiving IV furosemide infusion experienced significantly greater urine output and weight loss compared to those receiving placebo without any significant increase creatinine and no significant between group differences in echocardiography parameters, KCCQ or depression scores.</p>
                </sec>
                <sec id="sec004">
                  <title>Conclusion</title>
                  <p>The use of a standardized protocol of outpatient IV furosemide infusion for a one-month period following hospitalization for ADHF was found to be safe and efficacious in reducing 30-day re-hospitalization.</p>
                </sec>
              </abstract>
              <funding-group>
                <award-group id="award001">
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000050</institution-id>
                      <institution>National Heart, Lung, and Blood Institute</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>T32 HL007024</award-id>
                  <principal-award-recipient>
                    <contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7063-1727</contrib-id>
                    <name>
                      <surname>Hamo</surname>
                      <given-names>Carine E.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
                <funding-statement>Carine Hamo reports support from the National Heart, Lung, and Blood Institute, National Institutes of Health (Grant Number T32 HL007024). All other authors have no relationships to disclose.</funding-statement>
              </funding-group>
              <counts>
                <fig-count count="2"/>
                <table-count count="3"/>
                <page-count count="15"/>
              </counts>
              <custom-meta-group>
                <custom-meta id="data-availability">
                  <meta-name>Data Availability</meta-name>
                  <meta-value>All relevant data are within the manuscript and its <xref rid="pone.0253014.s001" ref-type="supplementary-material">S1</xref>–<xref rid="pone.0253014.s003" ref-type="supplementary-material">S3</xref> Figs, <xref rid="pone.0253014.s007" ref-type="supplementary-material">S1 File</xref>, <xref rid="pone.0253014.s004" ref-type="supplementary-material">S1</xref>–<xref rid="pone.0253014.s006" ref-type="supplementary-material">S3</xref> Tables.</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <title>Data Availability</title>
              <p>All relevant data are within the manuscript and its <xref rid="pone.0253014.s001" ref-type="supplementary-material">S1</xref>–<xref rid="pone.0253014.s003" ref-type="supplementary-material">S3</xref> Figs, <xref rid="pone.0253014.s007" ref-type="supplementary-material">S1 File</xref>, <xref rid="pone.0253014.s004" ref-type="supplementary-material">S1</xref>–<xref rid="pone.0253014.s006" ref-type="supplementary-material">S3</xref> Tables.</p>
            </notes>
          </front>
          <body>
            <sec sec-type="intro" id="sec005">
              <title>Introduction</title>
              <p>There continues to be a growing burden of heart failure (HF) due to rising prevalence coupled with extended, frequent hospitalizations with approximately one quarter of HF patients re-hospitalized within 30 days [<xref rid="pone.0253014.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0253014.ref002" ref-type="bibr">2</xref>]. HF management programs can reduce HF admissions by up to 80% with a multidisciplinary approach that provides early identification and intervention on symptom progression, patient education, and management of medical, socioeconomic, and psychologic factors that contribute to HF exacerbations [<xref rid="pone.0253014.ref003" ref-type="bibr">3</xref>–<xref rid="pone.0253014.ref008" ref-type="bibr">8</xref>].</p>
              <p>Over the past several decades, several trials have failed to demonstrate effective treatments for acute decompensated heart failure (ADHF) that improve long-term outcomes [<xref rid="pone.0253014.ref009" ref-type="bibr">9</xref>]. Diuretics remain the mainstay therapy for HF symptom management with escalation of dosing as needed for decongestion. Several studies have shown that outpatient intravenous (IV) diuretic therapy is safe, cost effective, and may stabilize evolving deterioration and prevent hospital readmissions [<xref rid="pone.0253014.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0253014.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0253014.ref011" ref-type="bibr">11</xref>]. However, there have been no randomized controlled trials to date that utilize outpatient IV furosemide diuretic maintenance treatment in patients with HF and reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF) following hospitalization for ADHF.</p>
              <p>The current study was a randomized controlled, double blinded study aimed to evaluate the feasibility, efficacy and safety of outpatient IV diuretic therapy in reducing 30 days re-hospitalization for ADHF following hospital admission.</p>
            </sec>
            <sec sec-type="materials|methods" id="sec006">
              <title>Methods</title>
              <sec id="sec007">
                <title>Study design</title>
                <p>OUTpatient Intravenous LASix Trial <bold>(</bold>OUTLAST) was a single center prospective randomized double-blind controlled trial. The study was approved by the Institutional Review Board of New York Presbyterian Brooklyn Methodist Hospital (Reference # 307139, approved 3/15/2012) and registered at <ext-link xlink:href="http://www.clinicaltrials.gov/" ext-link-type="uri">www.clinicaltrials.gov</ext-link> (NCT04691687). The trial was registered after patient recruitment began due to an oversight as it was thought to have been registered prior to study initiation. The authors confirm that all ongoing and related trials for this drug/intervention are registered. All patients provided written informed consent.</p>
              </sec>
              <sec id="sec008">
                <title>Study population</title>
                <p>Adult men and women &gt;18 years of age with a known history of systolic or diastolic dysfunction &gt;6 weeks, New York Heart Association (NYHA) Class II-IV, elevated n-terminal-pro brain natriuretic peptide (NT- proBNP) ≥360 pg/ml not explained by any other etiology presenting to the hospital emergency department between May 2012 and June 2017 with at least one symptom (paroxysmal nocturnal dyspnea, orthopnea, dyspnea on mild or moderate exertion) at the time of screening and at least one sign (rales post cough, jugular venous pressure ≥10 cm H<sub>2</sub>0, lower extremity edema, or chest x-ray demonstrating pleural effusion, pulmonary congestion, or cardiomegaly) were screened and evaluated for study eligibility. Patients with a systolic blood pressure (SBP) &lt;85 mmHg, signs of significant respiratory distress, biventricular intracardiac defibrillator (ICD) placement within 15 days, cardiogenic shock, acute renal failure or on chronic dialysis, severe systemic illness with life expectancy judged to be less than three years, chronic pulmonary disease requiring home oxygen, hemodynamically significant uncorrected valvular heart disease, or any valvular disease expected to lead to surgery during the trial, myocardial infarction in past 90 days, percutaneous coronary intervention in past 30 days, heart transplant or currently implanted left ventricular assist device, history of stroke in the past 90 days, allergy to lasix, known chronic hepatic disease, dementia or psychiatric illness, those blind or deaf and patients who were transferred to a different hospital were excluded.</p>
              </sec>
              <sec id="sec009">
                <title>Randomization and intervention</title>
                <p>Patients were randomized by a clinical pharmacist with the ratio of 1:1:1 into 3 groups: standard of care control arm (Group 1), IV placebo infusion (Group 2), and IV furosemide infusion (Group 3). (<bold><xref rid="pone.0253014.g001" ref-type="fig">Fig 1</xref></bold>) Patients in Group 2 and 3 received a comprehensive HF-care protocol that included bi-weekly clinic visits for dose-adjusted IV-diuretics, medication adjustment and education. Patients, nurses and treating physicians were blinded to the randomization. Patients in Group 1 received standard of care treatment per heart failure guidelines at the discretion of the primary cardiologist involved in the patient’s care [<xref rid="pone.0253014.ref008" ref-type="bibr">8</xref>]. Patients in Group 2 received IV saline infusion (20–40 ml) concentrated by the pharmacist to minimize fluid intake. Patients in Group 3 received IV furosemide (LASIX, Sanofi-Aventis U.S. LLC Bridgewater, New Jersey) calculated by the pharmacist to be equivalent or higher in dose compared to the patient’s home oral dose. The dose assignments were categorized into low dose (20 mg bolus with 20 mg/hour infusion sessions and 2 ml saline), intermediate dose (40 mg bolus with 40 mg/hour infusion sessions and 4 ml saline) and high dose (80 mg bolus with 80 mg/hour infusion sessions). The infusions were continuous over 3h, biweekly over a one-month period. Infusions were held at the discretion of the physician utilizing a written protocol (creatinine 25% above baseline, SBP &lt;80 mmHg or symptoms of presyncope). Patients in both Groups 2 and 3 resumed all of their oral home medications for HF post infusion visits per standard of care.</p>
                <fig position="float" id="pone.0253014.g001">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0253014.g001</object-id>
                  <label>Fig 1</label>
                  <caption>
                    <title>Overall study flow diagram.</title>
                    <p>CABG, coronary artery bypass graft; IV, intravenous; PCI, percutaneous coronary intervention.</p>
                  </caption>
                  <graphic xlink:href="pone.0253014.g001" position="float"/>
                </fig>
              </sec>
              <sec id="sec010">
                <title>Study visit monitoring</title>
                <p>Patients randomized into either Group 2 (placebo/saline infusion) or Group 3 (furosemide infusion) were followed up at the HF outpatient infusion unit twice a week (8 visits per group per month; 464 total visits in both groups). Hemodynamic monitoring was performed during each study visit including weights at the start (prior to infusion) and end of the clinic visit. Fluid input and urine output were quantified during the study visits. Baseline laboratory testing (including basic metabolic panel and NT- proBNP) was performed for all study groups at baseline and 30-day follow-up, regardless of the treatment arm. Laboratory testing was done at the beginning and end of each infusion visit for Groups 2 and 3. Patients in all groups were monitored for any potential symptoms or side effects.</p>
                <p>The infusion unit consisted of a multidisciplinary team that included a physician, pharmacist, and nurse. The infusion unit contained <ext-link xlink:href="https://www.sciencedirect.com/topics/medicine-and-dentistry/infusion" ext-link-type="uri">infusion</ext-link> chairs with cardiac <ext-link xlink:href="https://www.sciencedirect.com/topics/medicine-and-dentistry/telemetry" ext-link-type="uri">telemetry</ext-link>, local medication storage, and infusion equipment. At each clinic visit, a detailed medical history was obtained, HF education material was provided, and medications were administered. A clinical pharmacist performed detailed medication reconciliation and evaluated medication adherence.</p>
              </sec>
              <sec id="sec011">
                <title>Echocardiography</title>
                <p>Echocardiography was performed at the baseline visit and one month following the baseline visit. Left ventricular ejection fraction (LVEF) was calculated using the modified Simpson’s method. The left atrial (LA) volume was calculated using the biplane area-length technique. The LV end-diastolic diameter (LVDd), LV end-systolic diameter (LVDs), septal wall thickness (SWT), and posterior wall thickness (PWT) were measured using M-mode echocardiography [<xref rid="pone.0253014.ref012" ref-type="bibr">12</xref>]. Diastolic function was assessed using transmitral and tissue Doppler imaging at the septal mitral annulus. Peak early (E) and late transmitral filling velocities (A), E/A, the deceleration time of peak E velocity, early diastolic mitral annular velocity (e’), and E/e’ were measured. Right ventricular systolic pressure was quantified from the peak tricuspid regurgitation velocity based on the Bernoulli equation and factoring in right atrial pressure which was estimated from the inferior vena cava (IVC) diameter and the collapsibility index [<xref rid="pone.0253014.ref012" ref-type="bibr">12</xref>]. Patients were classified as HFpEF if LVEF was &gt;45% or HFrEF if LVEF was ≤45% on baseline echocardiography.</p>
              </sec>
              <sec id="sec012">
                <title>Quality of life and depression assessment</title>
                <p>Quality of life and depression were assessed at baseline and at 30 days using the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the Depression Scale Health Questionnaire (PHQ 9). The KCCQ is a validated, 23-item self-administered questionnaire for the evaluation of multiple aspects of HF patients’ health status with health domains that include physical functioning, symptom frequency and severity, social function, self-efficacy, social interference and overall quality of life [<xref rid="pone.0253014.ref013" ref-type="bibr">13</xref>]. The KCCQ scales are summarized into a single summary score ranging from 0–100, with higher scores reflecting better perceived health status. The PHQ-9 is a clinically validated self-administered 9-item questionnaire for depression [<xref rid="pone.0253014.ref014" ref-type="bibr">14</xref>]. Depression symptoms are stratified and scored as minimal (0–4), mild (5–9), or moderate-to-severe (10–27) with a score ≥10 considered clinically significant for depressive symptoms.</p>
              </sec>
              <sec id="sec013">
                <title>Study outcomes and follow-up</title>
                <p>The primary outcome was defined as 30 days re-hospitalization for ADHF. Outcome adjudication began following study enrollment for Group 1 and after first infusion for Groups 2 and 3. Secondary outcomes included hospitalization beyond 30 days for all cardiac causes, cardiovascular death or myocardial infarction, all-cause death, and changes in KCCQ and PHQ-9 score from baseline to 30 days of follow-up. The 30 days follow-up was obtained through a study clinic visit. After 30 days, outcome ascertainment was obtained through telephone interviews and hospital chart reviews.</p>
              </sec>
              <sec id="sec014">
                <title>Adverse event monitoring</title>
                <p>All episodes of clinical deterioration and adverse events prior to, during, or after the start of the infusion session were documented. Treatment-related <ext-link xlink:href="https://www.sciencedirect.com/topics/medicine-and-dentistry/hypokalemia" ext-link-type="uri">hypokalemia</ext-link> or hyponatremia were defined as serum <ext-link xlink:href="https://www.sciencedirect.com/topics/medicine-and-dentistry/potassium" ext-link-type="uri">potassium</ext-link> ≤3.5 mEq/l, and serum sodium &lt;130 mEq/l, respectively. Worsening renal function was defined as creatinine level elevation &gt;25% above baseline. Worsening hemodynamics included hypotension (defined as SBP &lt;80 mmHg) or symptoms of presyncope. Other symptoms including dizziness, weakness, ototoxicity, or palpitations following IV medication administration were documented.</p>
              </sec>
              <sec id="sec015">
                <title>Statistical analysis</title>
                <p>For continuous variables, mean and standard deviations were used if the data was normally distributed while median and interquartile ranges were applied for skewed data. For categorical variables, numbers and percentage were used. Baseline characteristics were presented in tabular form for the population as a whole, and in subgroups defined by treatment arm, as well as by HF categories (HFpEF vs HFrEF). The intergroup comparisons were performed by independent t-test or paired t-test for continuous variables and a chi-square test or McNemars test for categorical variables, as deemed appropriate.</p>
                <p>Primary outcomes were reported as rates of 30-day hospitalization. Rates of hospitalization and mortality were compared in a subgroup analysis based on HF classification (HFpEF vs HFrEF). Secondary outcomes were reported as beyond 30 days rates of hospitalization for all cardiac causes, cardiovascular death or myocardial infarction, all cause-death; and change in KCCQ and PHQ-9 scores. We report the percentage of patients with a 5-point change in the KCCQ overall summary score, KCCQ overall score &lt;45%, and PHQ-9 score cutoff ≥10, indicating a noticeable clinical difference, and major depressive symptoms, respectively.</p>
                <p>Feasibility of outpatient IV diuretic infusion was reported as the percentage of completed sessions. Safety of outpatient IV diuretic therapy in treating HF was reported as the percentage of adverse events occurring during infusion and within 30 days. Resolution of acute HF symptoms was evaluated by NYHA class at baseline infusion visit and at 30 days follow-up [<xref rid="pone.0253014.ref015" ref-type="bibr">15</xref>]. Post-hoc power “per protocol” analysis was conducted based on the observed primary outcome (30 days HF rehospitalization) in the Group 3 (IV furosemide) in comparison to each of the other groups (Group 1: control arm and Group 2: IV placebo infusion). Using two-sided alpha of 0.05 with at least 13% null difference using 2 proportional samples and a power of 90%, a total sample size of 94 was calculated. The study enrolled a total of 100 patients to account for attrition. Intention to treat analysis was also reported for comparing the primary outcome between the 3 groups.</p>
                <p>All statistical analyses were performed with JMP Pro 14.1 (SAS Cary, North Carolina). Statistical significance was set <italic toggle="yes">a priori</italic> as two tailed with p &lt;0.05.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sec016">
              <title>Results</title>
              <p>A total of 100 patients consented to the study and were randomized into 3 Groups (Group 1 = 36, Group 2 = 34, and Group 3 = 30). Of those 100 patients initially enrolled, 3 died (2 in Group 2, and 1 in Group 3) after randomization but before the start of the infusion clinic visits, 1 patient (Group 2) withdrew consent from the study, and 2 patients (Group 3) dropped out of the study prior to starting the infusion resulting in a final study population of 94 patients (Group 1 = 36, Group 2 = 31, and Group 3 = 27). (<bold><xref rid="pone.0253014.g001" ref-type="fig">Fig 1</xref></bold>) Patients in the final study population had a mean age of 64 ± 13 years, including 53 (56%) males, and 65 African Americans. A total of 66 (70%) patients had HFrEF, 89 (94%) had hypertension, and 53 (56%) had diabetes mellitus. A total of 80 (86%) patients were on home loop diuretics with a mean maintenance furosemide diuretic dose of 65 ± 44 mg/day. (<bold><xref rid="pone.0253014.t001" ref-type="table">Table 1</xref></bold>) Participants randomized to Group 3 (furosemide infusion), received low dose in 71% of the sessions, and intermediate dosing in 29% of the sessions. Patients with HFpEF were older (mean age 69 ± 12 years) and more likely to be female (74%) compared to those with HFrEF (mean age 62 ± 13 years, 32% female) (<bold><xref rid="pone.0253014.s004" ref-type="supplementary-material">S1 Table</xref></bold>).</p>
              <table-wrap position="float" id="pone.0253014.t001">
                <object-id pub-id-type="doi">10.1371/journal.pone.0253014.t001</object-id>
                <label>Table 1</label>
                <caption>
                  <title>Baseline characteristics categorized by treatment intervention.</title>
                </caption>
                <alternatives>
                  <graphic xlink:href="pone.0253014.t001" id="pone.0253014.t001g" position="float"/>
                  <table frame="hsides" rules="groups">
                    <colgroup span="1">
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                      <col align="left" valign="middle" span="1"/>
                    </colgroup>
                    <thead>
                      <tr>
                        <th align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">Demographics</th>
                        <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Overall population (n = 94)</th>
                        <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Group 1 (n = 36)</th>
                        <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Group 2 (n = 31)</th>
                        <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Group 3 (n = 27)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Age (years)</td>
                        <td align="center" rowspan="1" colspan="1">63.8 ± 12.9</td>
                        <td align="center" rowspan="1" colspan="1">62.8 ± 12.2</td>
                        <td align="center" rowspan="1" colspan="1">67 ± 12.9</td>
                        <td align="center" rowspan="1" colspan="1">61.6 ± 13.8</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Males, n (%)</td>
                        <td align="center" rowspan="1" colspan="1">53 (56.4%)</td>
                        <td align="center" rowspan="1" colspan="1">23 (63.9%)</td>
                        <td align="center" rowspan="1" colspan="1">15 (48.4%)</td>
                        <td align="center" rowspan="1" colspan="1">15 (55.6%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Race</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">    Caucasian</td>
                        <td align="center" rowspan="1" colspan="1">11 (11.7%)</td>
                        <td align="center" rowspan="1" colspan="1">5 (13.9%)</td>
                        <td align="center" rowspan="1" colspan="1">3 (9.7%)</td>
                        <td align="center" rowspan="1" colspan="1">3 (11.1%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">    African American</td>
                        <td align="center" rowspan="1" colspan="1">65 (69.1%)</td>
                        <td align="center" rowspan="1" colspan="1">26 (72.2%)</td>
                        <td align="center" rowspan="1" colspan="1">24 (77.4%)</td>
                        <td align="center" rowspan="1" colspan="1">15 (55.6%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">    Hispanic</td>
                        <td align="center" rowspan="1" colspan="1">12 (12.8%)</td>
                        <td align="center" rowspan="1" colspan="1">2 (5.6%)</td>
                        <td align="center" rowspan="1" colspan="1">3 (9.7%)</td>
                        <td align="center" rowspan="1" colspan="1">7 (25.9%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">    Other</td>
                        <td align="center" rowspan="1" colspan="1">6 (6.2%)</td>
                        <td align="center" rowspan="1" colspan="1">3 (8.3%)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3.2%)</td>
                        <td align="center" rowspan="1" colspan="1">2 (7.4%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Baseline weight (kg)</td>
                        <td align="center" rowspan="1" colspan="1">95.8 ± 29.5</td>
                        <td align="center" rowspan="1" colspan="1">90.6 ± 26.7</td>
                        <td align="center" rowspan="1" colspan="1">98.9 ± 35.9</td>
                        <td align="center" rowspan="1" colspan="1">99.4 ± 5.7</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td>
                        <td align="center" rowspan="1" colspan="1">32.3 ± 8.8</td>
                        <td align="center" rowspan="1" colspan="1">30.7 ± 9.2</td>
                        <td align="center" rowspan="1" colspan="1">32.1 ± 9.4</td>
                        <td align="center" rowspan="1" colspan="1">34.5 ± 6.9</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Obesity (BMI&gt; 30 kg/m<sup>2</sup>)</td>
                        <td align="center" rowspan="1" colspan="1">51 (54.3%)</td>
                        <td align="center" rowspan="1" colspan="1">14 (38.9%)</td>
                        <td align="center" rowspan="1" colspan="1">14 (45.2%)</td>
                        <td align="center" rowspan="1" colspan="1">23 (85.2%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HFrEF</td>
                        <td align="center" rowspan="1" colspan="1">66 (70.2%)</td>
                        <td align="center" rowspan="1" colspan="1">25 (69.4%)</td>
                        <td align="center" rowspan="1" colspan="1">20 (64.5%)</td>
                        <td align="center" rowspan="1" colspan="1">21 (80.8%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">HFpEF</td>
                        <td align="center" rowspan="1" colspan="1">27 (28.7%)</td>
                        <td align="center" rowspan="1" colspan="1">11 (30.6%)</td>
                        <td align="center" rowspan="1" colspan="1">11 (35.5%)</td>
                        <td align="center" rowspan="1" colspan="1">5 (19.2%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ICD implantation</td>
                        <td align="center" rowspan="1" colspan="1">29 (31.2%)</td>
                        <td align="center" rowspan="1" colspan="1">11 (30.6%)</td>
                        <td align="center" rowspan="1" colspan="1">12 (38.7%)</td>
                        <td align="center" rowspan="1" colspan="1">6 (23.1%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">CRT</td>
                        <td align="center" rowspan="1" colspan="1">4 (4.3%)</td>
                        <td align="center" rowspan="1" colspan="1">2 (5.6%)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3.2%)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3.9%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">History of atrial fibrillation</td>
                        <td align="center" rowspan="1" colspan="1">30 (31.9%)</td>
                        <td align="center" rowspan="1" colspan="1">13 (36.1%)</td>
                        <td align="center" rowspan="1" colspan="1">9 (29.0%)</td>
                        <td align="center" rowspan="1" colspan="1">8 (29.6%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Diabetes</td>
                        <td align="center" rowspan="1" colspan="1">53 (56.4%)</td>
                        <td align="center" rowspan="1" colspan="1">19 (52.8%)</td>
                        <td align="center" rowspan="1" colspan="1">21 (67.7%)</td>
                        <td align="center" rowspan="1" colspan="1">13 (48.2%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hypercholesterolemia</td>
                        <td align="center" rowspan="1" colspan="1">55 (59.1%)</td>
                        <td align="center" rowspan="1" colspan="1">20 (55.6%)</td>
                        <td align="center" rowspan="1" colspan="1">19 (61.3%)</td>
                        <td align="center" rowspan="1" colspan="1">16 (61.5%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hypertension</td>
                        <td align="center" rowspan="1" colspan="1">89 (94.7%)</td>
                        <td align="center" rowspan="1" colspan="1">33 (91.7%)</td>
                        <td align="center" rowspan="1" colspan="1">31 (100%)</td>
                        <td align="center" rowspan="1" colspan="1">25 (92.6%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Current smoking</td>
                        <td align="center" rowspan="1" colspan="1">13 (14.1%)</td>
                        <td align="center" rowspan="1" colspan="1">3 (8.6%)</td>
                        <td align="center" rowspan="1" colspan="1">6 (20.0%)</td>
                        <td align="center" rowspan="1" colspan="1">4 (14.8%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Renal disease</td>
                        <td align="center" rowspan="1" colspan="1">41 (51.1%)</td>
                        <td align="center" rowspan="1" colspan="1">15 (41.7%)</td>
                        <td align="center" rowspan="1" colspan="1">19 (61.3%)</td>
                        <td align="center" rowspan="1" colspan="1">14 (51.9%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">History of Cancer</td>
                        <td align="center" rowspan="1" colspan="1">6 (6.5%)</td>
                        <td align="center" rowspan="1" colspan="1">2 (5.6%)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3.2%)</td>
                        <td align="center" rowspan="1" colspan="1">3 (11.5%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Prior CAD</td>
                        <td align="center" rowspan="1" colspan="1">40 (42.5%)</td>
                        <td align="center" rowspan="1" colspan="1">13 (36.1%)</td>
                        <td align="center" rowspan="1" colspan="1">13 (41.9%)</td>
                        <td align="center" rowspan="1" colspan="1">14 (51.9%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Prior MI</td>
                        <td align="center" rowspan="1" colspan="1">12 (12.8%)</td>
                        <td align="center" rowspan="1" colspan="1">3 (8.3%)</td>
                        <td align="center" rowspan="1" colspan="1">4 (13.3%)</td>
                        <td align="center" rowspan="1" colspan="1">5 (19.2%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Prior CABG</td>
                        <td align="center" rowspan="1" colspan="1">12 (12.8%)</td>
                        <td align="center" rowspan="1" colspan="1">5 (13.9%)</td>
                        <td align="center" rowspan="1" colspan="1">3 (9.7%)</td>
                        <td align="center" rowspan="1" colspan="1">4 (14.8%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">COPD</td>
                        <td align="center" rowspan="1" colspan="1">20 (21.3%)</td>
                        <td align="center" rowspan="1" colspan="1">9 (25%)</td>
                        <td align="center" rowspan="1" colspan="1">7 (22.6%)</td>
                        <td align="center" rowspan="1" colspan="1">4 (14.8%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">OSA</td>
                        <td align="center" rowspan="1" colspan="1">17 (18.1%)</td>
                        <td align="center" rowspan="1" colspan="1">4 (11.1%)</td>
                        <td align="center" rowspan="1" colspan="1">8 (25.8%)</td>
                        <td align="center" rowspan="1" colspan="1">5 (18.5%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">PAD</td>
                        <td align="center" rowspan="1" colspan="1">5 (5.3%)</td>
                        <td align="center" rowspan="1" colspan="1">1 (2.8%)</td>
                        <td align="center" rowspan="1" colspan="1">3 (9.7%)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3.7%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Prior CVA</td>
                        <td align="center" rowspan="1" colspan="1">9 (9.6%)</td>
                        <td align="center" rowspan="1" colspan="1">4 (11.1%)</td>
                        <td align="center" rowspan="1" colspan="1">4 (12.9%)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3.7%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">History of depression</td>
                        <td align="center" rowspan="1" colspan="1">8 (8.6%)</td>
                        <td align="center" rowspan="1" colspan="1">1 (2.9%)</td>
                        <td align="center" rowspan="1" colspan="1">3 (9.7%)</td>
                        <td align="center" rowspan="1" colspan="1">4 (14.8%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">
                          <bold>Cardiac Medications</bold>
                        </td>
                        <td align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Aspirin</td>
                        <td align="center" rowspan="1" colspan="1">67 (73.6%)</td>
                        <td align="center" rowspan="1" colspan="1">24 (70.6%)</td>
                        <td align="center" rowspan="1" colspan="1">20 (66.7%)</td>
                        <td align="center" rowspan="1" colspan="1">23 (85.2%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Clopidogrel</td>
                        <td align="center" rowspan="1" colspan="1">12 (13.3%)</td>
                        <td align="center" rowspan="1" colspan="1">6 (17.7%)</td>
                        <td align="center" rowspan="1" colspan="1">2 (6.9%)</td>
                        <td align="center" rowspan="1" colspan="1">4 (14.8%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Beta blockers</td>
                        <td align="center" rowspan="1" colspan="1">79 (84.9%)</td>
                        <td align="center" rowspan="1" colspan="1">29 (80.6%)</td>
                        <td align="center" rowspan="1" colspan="1">24 (80.0%)</td>
                        <td align="center" rowspan="1" colspan="1">26 (96.3%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Calcium channel blockers</td>
                        <td align="center" rowspan="1" colspan="1">16 (17.4%)</td>
                        <td align="center" rowspan="1" colspan="1">5 (14.3%)</td>
                        <td align="center" rowspan="1" colspan="1">8 (26.7%)</td>
                        <td align="center" rowspan="1" colspan="1">3 (11.1%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ACE-I</td>
                        <td align="center" rowspan="1" colspan="1">54 (58.7%)</td>
                        <td align="center" rowspan="1" colspan="1">17 (48.6%)</td>
                        <td align="center" rowspan="1" colspan="1">17 (56.7%)</td>
                        <td align="center" rowspan="1" colspan="1">20 (74.1%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">ARB</td>
                        <td align="center" rowspan="1" colspan="1">15 (16.3%)</td>
                        <td align="center" rowspan="1" colspan="1">7 (20%)</td>
                        <td align="center" rowspan="1" colspan="1">6 (20%)</td>
                        <td align="center" rowspan="1" colspan="1">1 (3.7%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Loop diuretics: Furosemide</td>
                        <td align="center" rowspan="1" colspan="1">80 (86.0%)</td>
                        <td align="center" rowspan="1" colspan="1">30 (83.3%)</td>
                        <td align="center" rowspan="1" colspan="1">27 (90%)</td>
                        <td align="center" rowspan="1" colspan="1">23 (85.2%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Other diuretics</td>
                        <td align="center" rowspan="1" colspan="1">23 (25%)</td>
                        <td align="center" rowspan="1" colspan="1">7 (20%)</td>
                        <td align="center" rowspan="1" colspan="1">9 (30%)</td>
                        <td align="center" rowspan="1" colspan="1">7 (25.9%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Baseline loop diuretic dose, mg/dl</td>
                        <td align="center" rowspan="1" colspan="1">65.3 ± 43.6</td>
                        <td align="center" rowspan="1" colspan="1">67.1 ± 43.1</td>
                        <td align="center" rowspan="1" colspan="1">59.3 ± 28</td>
                        <td align="center" rowspan="1" colspan="1">70.4 ± 58.3</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Aldosterone antagonist</td>
                        <td align="center" rowspan="1" colspan="1">31 (33.7%)</td>
                        <td align="center" rowspan="1" colspan="1">11 (31.4%)</td>
                        <td align="center" rowspan="1" colspan="1">8 (26.7%)</td>
                        <td align="center" rowspan="1" colspan="1">12 (44.4%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Statin</td>
                        <td align="center" rowspan="1" colspan="1">68 (73.9%)</td>
                        <td align="center" rowspan="1" colspan="1">26 (74.3%)</td>
                        <td align="center" rowspan="1" colspan="1">25 (83.3%)</td>
                        <td align="center" rowspan="1" colspan="1">17 (62.9)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Nitrates</td>
                        <td align="center" rowspan="1" colspan="1">24 (26.1%)</td>
                        <td align="center" rowspan="1" colspan="1">8 (22.9%)</td>
                        <td align="center" rowspan="1" colspan="1">8 (26.7%)</td>
                        <td align="center" rowspan="1" colspan="1">8 (29.6%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Hydralazine</td>
                        <td align="center" rowspan="1" colspan="1">18 (19.6%)</td>
                        <td align="center" rowspan="1" colspan="1">9 (25.7%)</td>
                        <td align="center" rowspan="1" colspan="1">4 (13.3%)</td>
                        <td align="center" rowspan="1" colspan="1">5 (18.5%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Digoxin</td>
                        <td align="center" rowspan="1" colspan="1">7 (7.4%)</td>
                        <td align="center" rowspan="1" colspan="1">3 (8.3%)</td>
                        <td align="center" rowspan="1" colspan="1">4 (12.9%)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">
                          <bold>Baseline hemodynamics and NYHA class</bold>
                        </td>
                        <td align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">SBP (mmHg)</td>
                        <td align="center" rowspan="1" colspan="1">127.1 ± 21.7</td>
                        <td align="center" rowspan="1" colspan="1">125.4 ± 24.1</td>
                        <td align="center" rowspan="1" colspan="1">125 ± 19.7</td>
                        <td align="center" rowspan="1" colspan="1">131.6 ± 20.5</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">DBP (mmHg)</td>
                        <td align="center" rowspan="1" colspan="1">73.6 ± 12.4</td>
                        <td align="center" rowspan="1" colspan="1">71.7 ± 11.5</td>
                        <td align="center" rowspan="1" colspan="1">71.3 ± 11.5</td>
                        <td align="center" rowspan="1" colspan="1">78.6 ± 13.5</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Heart rate (bpm)</td>
                        <td align="center" rowspan="1" colspan="1">78.9 ± 24.1</td>
                        <td align="center" rowspan="1" colspan="1">80.4 ± 34.1</td>
                        <td align="center" rowspan="1" colspan="1">76 ± 15.1</td>
                        <td align="center" rowspan="1" colspan="1">80.1 ± 15.0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">NYHA Classification</td>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                        <td align="center" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">    I</td>
                        <td align="center" rowspan="1" colspan="1">0 (0%)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0%)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0%)</td>
                        <td align="center" rowspan="1" colspan="1">0 (0%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">    II</td>
                        <td align="center" rowspan="1" colspan="1">12 (12.9%)</td>
                        <td align="center" rowspan="1" colspan="1">6 (17.7%)</td>
                        <td align="center" rowspan="1" colspan="1">3 (10%)</td>
                        <td align="center" rowspan="1" colspan="1">3 (11.1%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">    III</td>
                        <td align="center" rowspan="1" colspan="1">25 (26.9%)</td>
                        <td align="center" rowspan="1" colspan="1">13 (38.1%)</td>
                        <td align="center" rowspan="1" colspan="1">8 (26.7%)</td>
                        <td align="center" rowspan="1" colspan="1">4 (14.8%)</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">    IV</td>
                        <td align="center" rowspan="1" colspan="1">54 (58.1%)</td>
                        <td align="center" rowspan="1" colspan="1">15 (44.1%)</td>
                        <td align="center" rowspan="1" colspan="1">19 (63.3%)</td>
                        <td align="center" rowspan="1" colspan="1">20 (74.1%)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#CCCCCC" rowspan="1" colspan="1">
                          <bold>Baseline Labs</bold>
                        </td>
                        <td align="left" style="background-color:#CCCCCC" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#CCCCCC" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#CCCCCC" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#CCCCCC" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">BUN (mmol/L)</td>
                        <td align="center" rowspan="1" colspan="1">29.8 ± 14</td>
                        <td align="center" rowspan="1" colspan="1">27.2 ± 12.6</td>
                        <td align="center" rowspan="1" colspan="1">32.2 ± 17.0</td>
                        <td align="center" rowspan="1" colspan="1">27.4 ± 11.6</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Serum creatinine (mg/dL)</td>
                        <td align="center" rowspan="1" colspan="1">1.27 ± .42</td>
                        <td align="center" rowspan="1" colspan="1">1.19 ± 0.4</td>
                        <td align="center" rowspan="1" colspan="1">1.37 ± 0.5</td>
                        <td align="center" rowspan="1" colspan="1">1.26 ± 0.4</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Serum sodium (mmol/L)</td>
                        <td align="center" rowspan="1" colspan="1">139.9 ± 3.1</td>
                        <td align="center" rowspan="1" colspan="1">140 ± 3</td>
                        <td align="center" rowspan="1" colspan="1">139.4 ± 3.6</td>
                        <td align="center" rowspan="1" colspan="1">140 ± 2.5</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Serum potassium (mmol/L)</td>
                        <td align="center" rowspan="1" colspan="1">4.27 ± .47</td>
                        <td align="center" rowspan="1" colspan="1">4.2 ± 0.1</td>
                        <td align="center" rowspan="1" colspan="1">4.4 ± 0.1</td>
                        <td align="center" rowspan="1" colspan="1">4.3 ± 0.1</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">NT-proBNP (pg/ml), median (IQR)</td>
                        <td align="center" rowspan="1" colspan="1">3234 (1755–6154)</td>
                        <td align="center" rowspan="1" colspan="1">4389 (2119–6550)</td>
                        <td align="center" rowspan="1" colspan="1">3227 (1283–5104)</td>
                        <td align="center" rowspan="1" colspan="1">3151 (1796–7294)</td>
                      </tr>
                      <tr>
                        <td align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1">
                          <bold>Baseline Echocardiography</bold>
                        </td>
                        <td align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1"/>
                        <td align="left" style="background-color:#D9D9D9" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">LVEF, %</td>
                        <td align="center" rowspan="1" colspan="1">33.5 ± 19.3</td>
                        <td align="center" rowspan="1" colspan="1">33.6 ± 18.6</td>
                        <td align="center" rowspan="1" colspan="1">36.2 ± 20.1</td>
                        <td align="center" rowspan="1" colspan="1">30.3 ± 19.7</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">LVEDd, cm</td>
                        <td align="center" rowspan="1" colspan="1">5.5 ± 1.1</td>
                        <td align="center" rowspan="1" colspan="1">5.6 ± 1.2</td>
                        <td align="center" rowspan="1" colspan="1">5.2 ± 1.1</td>
                        <td align="center" rowspan="1" colspan="1">5.7 ± 0.94</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">LVESd, cm</td>
                        <td align="center" rowspan="1" colspan="1">4.6 ± 1.4</td>
                        <td align="center" rowspan="1" colspan="1">4.6 ± 1.5</td>
                        <td align="center" rowspan="1" colspan="1">4.5 ± 1.2</td>
                        <td align="center" rowspan="1" colspan="1">4.6 ± 1.6</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Stroke Volume, ml</td>
                        <td align="center" rowspan="1" colspan="1">47.6 ± 15.5</td>
                        <td align="center" rowspan="1" colspan="1">45.2 ± 15.1</td>
                        <td align="center" rowspan="1" colspan="1">49.9 ± 16.0</td>
                        <td align="center" rowspan="1" colspan="1">48.3 ± 16.0</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Left atrial volume, cc</td>
                        <td align="center" rowspan="1" colspan="1">94.2 ± 34.1</td>
                        <td align="center" rowspan="1" colspan="1">93.2 ± 36.3</td>
                        <td align="center" rowspan="1" colspan="1">94.9 ± 25.1</td>
                        <td align="center" rowspan="1" colspan="1">94.9 ± 41.1</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">RVSP, mmHg</td>
                        <td align="center" rowspan="1" colspan="1">49 ± 15.3</td>
                        <td align="center" rowspan="1" colspan="1">51.3 ± 15.9</td>
                        <td align="center" rowspan="1" colspan="1">50.1 ± 18.1</td>
                        <td align="center" rowspan="1" colspan="1">45.1 ± 11.3</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Mitral E</td>
                        <td align="center" rowspan="1" colspan="1">93.9 ± 40.3</td>
                        <td align="center" rowspan="1" colspan="1">88.0 ± 43.0</td>
                        <td align="center" rowspan="1" colspan="1">102.4 ± 35.3</td>
                        <td align="center" rowspan="1" colspan="1">92.8 ± 41.7</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Mitral A</td>
                        <td align="center" rowspan="1" colspan="1">53.1 ± 31.2</td>
                        <td align="center" rowspan="1" colspan="1">48.2 ± 30.4</td>
                        <td align="center" rowspan="1" colspan="1">62.4 ± 29.6</td>
                        <td align="center" rowspan="1" colspan="1">48.9 ± 33.3</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">E/A</td>
                        <td align="center" rowspan="1" colspan="1">2.28 ± 1.4</td>
                        <td align="center" rowspan="1" colspan="1">2.4 ± 1.7</td>
                        <td align="center" rowspan="1" colspan="1">2.1 ± 1.2</td>
                        <td align="center" rowspan="1" colspan="1">2.3 ± 1.1</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">e’</td>
                        <td align="center" rowspan="1" colspan="1">7.83 ± 3.2</td>
                        <td align="center" rowspan="1" colspan="1">7.5 ± 2.8</td>
                        <td align="center" rowspan="1" colspan="1">8.2 ± 2.8</td>
                        <td align="center" rowspan="1" colspan="1">7.8 ± 4.2</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">E/e’</td>
                        <td align="center" rowspan="1" colspan="1">13.7 ± 7.03</td>
                        <td align="center" rowspan="1" colspan="1">12.0 ± 7.6</td>
                        <td align="center" rowspan="1" colspan="1">14.2 ± 6.6</td>
                        <td align="center" rowspan="1" colspan="1">15.2 ± 6.6</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">Deceleration time, ms</td>
                        <td align="center" rowspan="1" colspan="1">155.6 ± 57.5</td>
                        <td align="center" rowspan="1" colspan="1">154.9 ± 55.4</td>
                        <td align="center" rowspan="1" colspan="1">149.2 ± 57.5</td>
                        <td align="center" rowspan="1" colspan="1">162.3 ± 62.3</td>
                      </tr>
                      <tr>
                        <td align="left" rowspan="1" colspan="1">IVC diameter, cm</td>
                        <td align="center" rowspan="1" colspan="1">2.08 ± 0.61</td>
                        <td align="center" rowspan="1" colspan="1">2.18 ± 0.60</td>
                        <td align="center" rowspan="1" colspan="1">1.99 ± 0.69</td>
                        <td align="center" rowspan="1" colspan="1">2.06 ± 0.48</td>
                      </tr>
                    </tbody>
                  </table>
                </alternatives>
                <table-wrap-foot>
                  <fn id="t001fn001">
                    <p>Data are expressed as the mean ± SD or number (%) patients or median (Interquartile range). P-values between the three intervention groups obtained from ANOVA test.</p>
                  </fn>
                  <fn id="t001fn002">
                    <p>ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BUN, blood urea nitrogen; CABG, coronary artery bypass graft; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CVA, cerebrovascular accident; DBP, diastolic blood pressure; HFpEF, heart failure preserved ejection fraction; HFrEF, heart failure reduced ejection fraction; ICD, intracardiac defibrillator; LVEDd, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; LVESs, left ventricular end systolic diameter; MI, myocardial infarction; NT-proBNP, N-terminal-pro brain natriuretic peptide; NYHA, New York Heart Association; OSA, obstructive sleep apnea; PAD, peripheral arterial disease; RVSP, right ventricular systolic pressure; SBP, systolic blood pressure.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <sec id="sec017">
                <title>Infusion visit metrics</title>
                <p>A total of 323 of 464 (69.6%) visits were completed for both Groups 2 and 3. Group 2 completed 167 of 248 (67.3%) planned visits while Group 3 completed 156 of 216 (72.2%) visits. Furosemide diuretics doses in Group 3 were categorized into low (20mg bolus with 20 mg/hr) in 110 of 156 (71%) sessions, intermediate (40 mg bolus with 40 mg/hr) in 46 sessions of 156 (29.5%) sessions and high (80 mg bolus with 80 mg/ hr) in 0 sessions. Overall, infusion sessions were completed as follows: 8 infusion visits in 23 patients, 7 infusion visits in 5 patients, 6 infusion visits in 5 patients, 5 infusion visits in 5 patients, 4 infusion visits in 5 patients, 3 infusion visits in 3 patients, 2 infusion visits in 1 patient, and 1 infusion visit in 9 patients.</p>
                <p>Patients in Group 3 achieved greater weight loss compared to those in Group 2 (mean weight loss of 0.72 kg in Group 3 vs 0.15 kg in Group 2, p &lt;0.0001). Urine output was greater in the Group 3 compared to Group 2 (mean difference of 794.5 ml vs 79.2 ml respectively, p &lt;0.0001). (<bold><xref rid="pone.0253014.g002" ref-type="fig">Fig 2</xref></bold>) Patients in Group 3 with HFrEF exhibited greater weight loss and urine output compared to those with HFpEF (mean weight loss of 0.79 kg vs 0.45 kg, respectively, p = .04, and mean urine output difference of 861 ml vs 468 ml respectively, p = .0002) (<bold><xref rid="pone.0253014.s005" ref-type="supplementary-material">S2 Table</xref></bold>).</p>
                <fig position="float" id="pone.0253014.g002">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0253014.g002</object-id>
                  <label>Fig 2</label>
                  <caption>
                    <title>Study outcomes across randomization groups.</title>
                    <p>Patients randomized to Group 1 (standard of care), Group 2 (intravenous placebo infusion), and Group 3 (intravenous furosemide infusion). Groups 2 and 3 underwent biweekly infusion visits for 30 days that included a HF-Care protocol. Changes in weight (a) and urine output (b) post- vs. pre-infusion for Group 2 and Group 3. Primary study outcome results (c) 30-day rehospitalization for ADHF in all three groups. ADHF, acute decompensated heart failure; HF, heart failure; IV, intravenous.</p>
                  </caption>
                  <graphic xlink:href="pone.0253014.g002" position="float"/>
                </fig>
                <p>There was a significant difference in SBP (4.8 mmHg) in Group 3 comparing pre- and post-infusion but no other significant hemodynamic differences in Group 3 or Group 2. There was a trend towards NYHA class improvement in Group 3 compared to Group 2. Laboratory values did not change significantly between the 3 groups from baseline to 30-day follow-up, apart from a significant difference in potassium levels and a trend towards significant NT-proBNP reduction in Group 3. (<bold><xref rid="pone.0253014.t002" ref-type="table">Table 2</xref></bold>) Echocardiographic parameters such as ejection fraction, end systolic and diastolic volumes as well as diastolic parameters were unchanged from baseline to 30-day follow-up across the 3 groups (<bold><xref rid="pone.0253014.t003" ref-type="table">Table 3</xref>, <xref rid="pone.0253014.s001" ref-type="supplementary-material">S1</xref>–<xref rid="pone.0253014.s003" ref-type="supplementary-material">S3</xref> Figs</bold>).</p>
                <table-wrap position="float" id="pone.0253014.t002">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0253014.t002</object-id>
                  <label>Table 2</label>
                  <caption>
                    <title>Infusion visit metrics changes (post infusion-pre infusion) categorized by intervention group.</title>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="pone.0253014.t002" id="pone.0253014.t002g" position="float"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="2" style="background-color:#D9D9D9" colspan="1"/>
                          <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Group 2</th>
                          <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Group 3</th>
                          <th align="center" rowspan="2" style="background-color:#D9D9D9" colspan="1"><xref rid="t002fn002" ref-type="table-fn">*</xref>p-value (Between Groups)</th>
                        </tr>
                        <tr>
                          <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">(n = 31)</th>
                          <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">(n = 27)</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Weight, kg</td>
                          <td align="center" rowspan="1" colspan="1">-0.15 (.07)<xref rid="t002fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">- 0.72 (.08)<xref rid="t002fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">&lt; .0001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Systolic blood pressure, mmHg</td>
                          <td align="center" rowspan="1" colspan="1">-0.85 (1.3)<xref rid="t002fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">- 4.8 (1.4)<xref rid="t002fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">.047</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Diastolic blood pressure, mmHg</td>
                          <td align="center" rowspan="1" colspan="1">2.2 (.96) <xref rid="t002fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">0.52 (.89)</td>
                          <td align="center" rowspan="1" colspan="1">.191</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Heart Rate, bpm</td>
                          <td align="center" rowspan="1" colspan="1">0.96 (3.4)</td>
                          <td align="center" rowspan="1" colspan="1">- 0.61 (.64)</td>
                          <td align="center" rowspan="1" colspan="1">.657</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Urine output, ml</td>
                          <td align="center" rowspan="1" colspan="1">79.2 (26.2)<xref rid="t002fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">794.5 (52.7)<xref rid="t002fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">&lt; .0001</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Serum sodium, mmol/L</td>
                          <td align="center" rowspan="1" colspan="1">-1.29 (0.47) <xref rid="t002fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">-1.13 (0.29)<xref rid="t002fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">.771</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Serum potassium, mmol/L</td>
                          <td align="center" rowspan="1" colspan="1">-0.09 (.06)</td>
                          <td align="center" rowspan="1" colspan="1">-0.14 (.05)<xref rid="t002fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">.518</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">BUN, mmol/L</td>
                          <td align="center" rowspan="1" colspan="1">-0.86 (0.32)<xref rid="t002fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">- 0.007 (0.3)</td>
                          <td align="center" rowspan="1" colspan="1">.053</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Serum creatinine, mg/dL</td>
                          <td align="center" rowspan="1" colspan="1">-0.03 (0.012)<xref rid="t002fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">0.006 (.015)</td>
                          <td align="center" rowspan="1" colspan="1">.109</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t002fn001">
                      <p>Data presented as mean difference and standard error (SE) between post-infusion versus pre-infusion values.</p>
                    </fn>
                    <fn id="t002fn002">
                      <p>*p-values obtained from independent t test or non-parametric test if data is skewed.</p>
                    </fn>
                    <fn id="t002fn003">
                      <p><sup>¥</sup>p-value &lt; .05, obtained from student’s paired t-test within each group of intervention (post-infusion vast value–pre-infusion visit value).</p>
                    </fn>
                    <fn id="t002fn004">
                      <p>BUN, blood urea nitrogen.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap position="float" id="pone.0253014.t003">
                  <object-id pub-id-type="doi">10.1371/journal.pone.0253014.t003</object-id>
                  <label>Table 3</label>
                  <caption>
                    <title>Changes in study outcome at 30 days compared to baseline categorized by treatment intervention group.</title>
                  </caption>
                  <alternatives>
                    <graphic xlink:href="pone.0253014.t003" id="pone.0253014.t003g" position="float"/>
                    <table frame="hsides" rules="groups">
                      <colgroup span="1">
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                        <col align="left" valign="middle" span="1"/>
                      </colgroup>
                      <thead>
                        <tr>
                          <th align="left" rowspan="2" style="background-color:#D9D9D9" colspan="1"/>
                          <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Group 1</th>
                          <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Group 2</th>
                          <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">Group 3</th>
                          <th align="center" rowspan="2" style="background-color:#D9D9D9" colspan="1"><xref rid="t003fn002" ref-type="table-fn">*</xref>p-value between groups</th>
                        </tr>
                        <tr>
                          <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">(n = 36)</th>
                          <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">(n = 31)</th>
                          <th align="center" style="background-color:#D9D9D9" rowspan="1" colspan="1">(n = 27)</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td align="left" colspan="5" style="background-color:#D9D9D9" rowspan="1">
                            <bold>Biometrics and Hemodynamics</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Weight (kg)</td>
                          <td align="center" rowspan="1" colspan="1">-0.28 (1.06)</td>
                          <td align="center" rowspan="1" colspan="1">0.28 (1.05)</td>
                          <td align="center" rowspan="1" colspan="1">-2.5 (1.06) <xref rid="t003fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">.185</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Systolic blood pressure, mmHg</td>
                          <td align="center" rowspan="1" colspan="1">-2.4 (4.7)</td>
                          <td align="center" rowspan="1" colspan="1">7.92 (3.9)</td>
                          <td align="center" rowspan="1" colspan="1">-10.7 (3.5) <xref rid="t003fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">.017</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Diastolic blood pressure, mmHg</td>
                          <td align="center" rowspan="1" colspan="1">0.64 (2.7)</td>
                          <td align="center" rowspan="1" colspan="1">1.56 (2.5)</td>
                          <td align="center" rowspan="1" colspan="1">-9.6 (3.2) <xref rid="t003fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">.012</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Heart rate, bpm</td>
                          <td align="center" rowspan="1" colspan="1">-2.28 (2.5)</td>
                          <td align="center" rowspan="1" colspan="1">3.64 (1.9)</td>
                          <td align="center" rowspan="1" colspan="1">-5.7 (2.9)</td>
                          <td align="center" rowspan="1" colspan="1">.03</td>
                        </tr>
                        <tr>
                          <td align="center" colspan="5" style="background-color:#D9D9D9" rowspan="1">
                            <bold>Symptomatology and Questionnaires</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Change in NYHA Class</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    No change</td>
                          <td align="center" rowspan="1" colspan="1">7 (24%)</td>
                          <td align="center" rowspan="1" colspan="1">8 (30.8%)</td>
                          <td align="center" rowspan="1" colspan="1">7 (33.3%)</td>
                          <td align="center" rowspan="4" colspan="1">.934</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    Improvement by 1 class</td>
                          <td align="center" rowspan="1" colspan="1">11 (37.9%)</td>
                          <td align="center" rowspan="1" colspan="1">11 (42.3%)</td>
                          <td align="center" rowspan="1" colspan="1">7 (33.3%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    Improvement by 2 classes</td>
                          <td align="center" rowspan="1" colspan="1">2 (6.9%)</td>
                          <td align="center" rowspan="1" colspan="1">3 (11.5%)</td>
                          <td align="center" rowspan="1" colspan="1">3 (14.3%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    Improvement by 3 classes</td>
                          <td align="center" rowspan="1" colspan="1">2 (6.9%)</td>
                          <td align="center" rowspan="1" colspan="1">3 (11.5%)</td>
                          <td align="center" rowspan="1" colspan="1">3 (14.3%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Change in KCCQ scores, median (IQR):</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    Total symptom score</td>
                          <td align="center" rowspan="1" colspan="1">14.1 (-5.5–35.4) <xref rid="t003fn004" ref-type="table-fn"><sup>€</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">17.7 (-1.3–37.5) <xref rid="t003fn004" ref-type="table-fn"><sup>€</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">7.3 (-2.6–38.5) <xref rid="t003fn004" ref-type="table-fn"><sup>€</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">.868</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    Overall summary score</td>
                          <td align="center" rowspan="1" colspan="1">15.4 (3.3–26.9) <xref rid="t003fn004" ref-type="table-fn"><sup>€</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">23.9 (11.9–31.01)<xref rid="t003fn004" ref-type="table-fn"><sup>€</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">17.2 (4.7–35.2) <xref rid="t003fn004" ref-type="table-fn"><sup>€</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">.264</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    Clinical summary score</td>
                          <td align="center" rowspan="1" colspan="1">9.1 (-5.9–19.6) <xref rid="t003fn004" ref-type="table-fn"><sup>€</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">10.7 (.78–22.0)<xref rid="t003fn004" ref-type="table-fn"><sup>€</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">6.3 (-1.04–16.1) <xref rid="t003fn004" ref-type="table-fn"><sup>€</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">.424</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Change in Overall KCCQ summary score</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    Decrease (≥5 point)</td>
                          <td align="center" rowspan="1" colspan="1">3 (10.3%)</td>
                          <td align="center" rowspan="1" colspan="1">1 (4.0%)</td>
                          <td align="center" rowspan="1" colspan="1">1 (4.6%)</td>
                          <td align="center" rowspan="3" colspan="1">.693</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    No change (&lt;5 point)</td>
                          <td align="center" rowspan="1" colspan="1">4 (13.8%)</td>
                          <td align="center" rowspan="1" colspan="1">2 (8.0%)</td>
                          <td align="center" rowspan="1" colspan="1">4 (18.2%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    Increase (≥5 point)</td>
                          <td align="center" rowspan="1" colspan="1">22 (75.9%)</td>
                          <td align="center" rowspan="1" colspan="1">22 (88%)</td>
                          <td align="center" rowspan="1" colspan="1">17 (77.3%)</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">KCCQ Overall score &lt;45, % Baseline</td>
                          <td align="center" rowspan="1" colspan="1">9 (31%)</td>
                          <td align="center" rowspan="1" colspan="1">8 (30.8%)</td>
                          <td align="center" rowspan="1" colspan="1">7 (33.3%)</td>
                          <td align="center" rowspan="1" colspan="1">.979</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Change in PHQ-9, median (IQR)</td>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                          <td align="center" rowspan="1" colspan="1"/>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">    Baseline PHQ-9 ≥10</td>
                          <td align="center" rowspan="1" colspan="1">-3.4 (-6.5–0) <xref rid="t003fn004" ref-type="table-fn"><sup>€</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">-0.5 (-2.5–1.5)</td>
                          <td align="center" rowspan="1" colspan="1">-2.5 (-7.5–0) <xref rid="t003fn004" ref-type="table-fn"><sup>€</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">.291</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="2" colspan="1">    30-day PHQ-9 ≥10</td>
                          <td align="center" rowspan="1" colspan="1">13 (36.1%)</td>
                          <td align="center" rowspan="1" colspan="1">8 (25.8%)</td>
                          <td align="center" rowspan="1" colspan="1">11 (42.3%)</td>
                          <td align="center" rowspan="1" colspan="1">.410</td>
                        </tr>
                        <tr>
                          <td align="center" rowspan="1" colspan="1">4 (13.3%)</td>
                          <td align="center" rowspan="1" colspan="1">5 (19.2%)</td>
                          <td align="center" rowspan="1" colspan="1">4 (19.1%)</td>
                          <td align="center" rowspan="1" colspan="1">.802</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="5" style="background-color:#CCCCCC" rowspan="1">
                            <bold>Labs</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Serum BUN, mmol/L</td>
                          <td align="center" rowspan="1" colspan="1">-0.94 (2.5)</td>
                          <td align="center" rowspan="1" colspan="1">-0.96 (2.5)</td>
                          <td align="center" rowspan="1" colspan="1">3.4 (3.3)</td>
                          <td align="center" rowspan="1" colspan="1">.376</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Serum creatinine, mg/ld.</td>
                          <td align="center" rowspan="1" colspan="1">0.21 (0.09) <xref rid="t003fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">.04 (.08)</td>
                          <td align="center" rowspan="1" colspan="1">0.15 (.06) <xref rid="t003fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">.333</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Serum sodium, mmol/L</td>
                          <td align="center" rowspan="1" colspan="1">-0.703 (0.66)</td>
                          <td align="center" rowspan="1" colspan="1">-2.04 (.65)<xref rid="t003fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">-0.77 (0.7)</td>
                          <td align="center" rowspan="1" colspan="1">.248</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Serum potassium, mmol/L</td>
                          <td align="center" rowspan="1" colspan="1">0.27 (0.12) <xref rid="t003fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">-0.23 (0.12)</td>
                          <td align="center" rowspan="1" colspan="1">.02 (0.12)</td>
                          <td align="center" rowspan="1" colspan="1">.014</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">NT-proBNP, pg/ml</td>
                          <td align="center" rowspan="1" colspan="1">-2586.3 (822) <xref rid="t003fn003" ref-type="table-fn"><sup>¥</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">2416.5 (3481.3)</td>
                          <td align="center" rowspan="1" colspan="1">-5253.3 (3043.5)</td>
                          <td align="center" rowspan="1" colspan="1">.152</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="5" style="background-color:#D9D9D9" rowspan="1">
                            <bold>Echocardiography</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">LVEF, %</td>
                          <td align="center" rowspan="1" colspan="1">2.8 (1.7)</td>
                          <td align="center" rowspan="1" colspan="1">2.05 (1.2)</td>
                          <td align="center" rowspan="1" colspan="1">2.0 (2.6)</td>
                          <td align="center" rowspan="1" colspan="1">.931</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">LVEDd, cm</td>
                          <td align="center" rowspan="1" colspan="1">.37 (.2)</td>
                          <td align="center" rowspan="1" colspan="1">0.45(.23)</td>
                          <td align="center" rowspan="1" colspan="1">0.35 (.25)</td>
                          <td align="center" rowspan="1" colspan="1">.945</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">LVESd, cm</td>
                          <td align="center" rowspan="1" colspan="1">.34 (.15)</td>
                          <td align="center" rowspan="1" colspan="1">.04(.17)</td>
                          <td align="center" rowspan="1" colspan="1">0.37 (.18)</td>
                          <td align="center" rowspan="1" colspan="1">.246</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Stroke Volume, ml</td>
                          <td align="center" rowspan="1" colspan="1">12.6 (5.1)</td>
                          <td align="center" rowspan="1" colspan="1">4.9(6.5)</td>
                          <td align="center" rowspan="1" colspan="1">11.8 (6.9)</td>
                          <td align="center" rowspan="1" colspan="1">.644</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Left atrial volume, cc</td>
                          <td align="center" rowspan="1" colspan="1">-.58 (5.8)</td>
                          <td align="center" rowspan="1" colspan="1">-9.8(5.4)</td>
                          <td align="center" rowspan="1" colspan="1">1.5 (8.2)</td>
                          <td align="center" rowspan="1" colspan="1">.344</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">RVSP, mmHg</td>
                          <td align="center" rowspan="1" colspan="1">-9.2 (3.1)</td>
                          <td align="center" rowspan="1" colspan="1">-8.3 (3.4)</td>
                          <td align="center" rowspan="1" colspan="1">-4.5 (3.8)</td>
                          <td align="center" rowspan="1" colspan="1">.575</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">E/e’</td>
                          <td align="center" rowspan="1" colspan="1">3.7 (2.1)</td>
                          <td align="center" rowspan="1" colspan="1">0.82 (2.2)</td>
                          <td align="center" rowspan="1" colspan="1">-.8 (2.4)</td>
                          <td align="center" rowspan="1" colspan="1">.112</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">IVC diameter, cm</td>
                          <td align="center" rowspan="1" colspan="1">0.38 (0.13)</td>
                          <td align="center" rowspan="1" colspan="1">0.17 (0.15)</td>
                          <td align="center" rowspan="1" colspan="1">0.05 (0.12)</td>
                          <td align="center" rowspan="1" colspan="1">.315</td>
                        </tr>
                        <tr>
                          <td align="left" colspan="5" style="background-color:#DFDFDF" rowspan="1">
                            <bold>Events at 30 days</bold>
                          </td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Re hospitalization for HF</td>
                          <td align="center" rowspan="1" colspan="1">6 (17.1%)</td>
                          <td align="center" rowspan="1" colspan="1">7 (22.6%)<xref rid="t003fn005" ref-type="table-fn"><sup>#</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">1 (3.7%)<xref rid="t003fn005" ref-type="table-fn"><sup>#</sup></xref></td>
                          <td align="center" rowspan="1" colspan="1">.107</td>
                        </tr>
                        <tr>
                          <td align="left" rowspan="1" colspan="1">Cardiac hospitalization for non- HF causes</td>
                          <td align="center" rowspan="1" colspan="1">4 (11.8%)</td>
                          <td align="center" rowspan="1" colspan="1">2 (6.7%)</td>
                          <td align="center" rowspan="1" colspan="1">1 (3.7)</td>
                          <td align="center" rowspan="1" colspan="1">.619</td>
                        </tr>
                      </tbody>
                    </table>
                  </alternatives>
                  <table-wrap-foot>
                    <fn id="t003fn001">
                      <p>Data presented as mean difference and standard error (SE) between baseline versus 30-day values.</p>
                    </fn>
                    <fn id="t003fn002">
                      <p>*p-values between the three intervention groups obtained from ANOVA test.</p>
                    </fn>
                    <fn id="t003fn003">
                      <p><sup>¥</sup> p-values &lt; .05, obtained from student’s paired t-test within each group (30 days follow-up value-baseline value).</p>
                    </fn>
                    <fn id="t003fn004">
                      <p><sup>€</sup>p-values &lt; .05, obtained from Wilcoxon signed rank test paired t-test for non-parametric skewed data within each group (30 days follow-up value—baseline value).</p>
                    </fn>
                    <fn id="t003fn005">
                      <p><sup>#</sup>Comparing 30-day hospitalization between group 2 and group 3, p = .037.</p>
                    </fn>
                    <fn id="t003fn006">
                      <p>BUN, blood urea nitrogen; HF, heart failure; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEDd, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; LVESs, left ventricular end systolic diameter; NT-proBNP, N-terminal-pro brain natriuretic peptide; NYHA, New York Heart Association; PHQ-9, Patient Health Questionnaire-9; RVSP, right ventricular systolic pressure.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>Adverse events before or during the start of infusion were reported in 28/464 (6%) visits with 17 events in Group 2 and 11 events in Group 3. These included hypotension in 2 visits, increase in serum creatinine in 9 visits, hypokalemia in 6 visits, hypomagnesemia in 5 visits, hyperkalemia in 2 visits, symptomatology of chest pain in 1, shortness of breath in 1, and runs of non-sustained ventricular tachycardia in 2 visits.</p>
              </sec>
              <sec id="sec018">
                <title>30-day follow-up results</title>
                <p>Out of 94 patients, 93 (99%) completed the 30 days follow-up clinic visit. There were a total of 14 (15%) hospitalizations for ADHF at 30 days, 6 (17.1%) in Group 1, 7 (22.6%) in Group 2, and 1 (3.7%) in Group 3 (p = 0.037 comparing Group 2 and Group 3). (<bold><xref rid="pone.0253014.g002" ref-type="fig">Fig 2</xref></bold>) Similarly, the intention to treat analysis showed a total of 15 (15%) hospitalizations for ADHF at 30 days, 6 (17.1%) in Group 1, 8 (23.5%) in Group 2, and 1 (3.7%) in Group 3 (p = 0.020 comparing Group 2 and Group 3).</p>
                <p>At 30 days follow-up, there were no cardiac or non-cardiac deaths. A total of 7 (8%) patients experienced 30 days hospitalization for causes other than HF (uncontrolled hypertension in 2 patients (Group 1), chest pain in 2 patients (Group 2), scalp abscess in 1 patient (Group 1), ICD shock for polymorphic VT in 1 patient (Group 3), and bowel obstruction for 1 patient (Group 1)). (<bold><xref rid="pone.0253014.t003" ref-type="table">Table 3</xref></bold>) There were no significant differences in outcomes among participants with HFrEF versus HFpEF (<bold><xref rid="pone.0253014.s006" ref-type="supplementary-material">S3 Table</xref></bold>).</p>
              </sec>
              <sec id="sec019">
                <title>Beyond 30-day follow-up results</title>
                <p>Beyond 30-day follow-up was available in 90 patients <bold>(</bold>2.8 ± 2.2 years). At 180 days of follow-up, hospitalizations for ADHF were reported in a total of 31 (34.4%) patients, 11 (36.7%) in Group 1, 12 (42.9%) in Group 2, and 7 (30.8%) in Group 3. Hospitalization for causes other than HF was reported in 14 (16.4%) patients. Of those, 1 patient was hospitalized for hypotension, 4 patients with cerebrovascular accident (CVA)/transient ischemic attack (TIA), 2 patients with chest pain/acute coronary syndrome (ACS), 1 patient with syncope, and the remainder were hospitalized for non-cardiac causes.</p>
                <p>Beyond 180 days of follow-up, hospitalizations for ADHF were reported in 44 (48.9%) patients, 14 (50%) in Group 1, 16 (57%) in Group 2, and 14 (56%) in Group 3. Hospitalization for causes other than HF were reported in 43 (53%) patients. Of those, 1 patient was hospitalized for hypertensive emergency, 2 for ICD implantation, 1 with chest pain/ACS, 2 patients with hypotension/syncope, and the remainder for non-cardiac causes.</p>
                <p>All cause-mortality during the study follow-up period beyond the 30 days occurred in 16 (17.7%) patients (5 (13.8%) in Group 1, 8 (25.8%) in Group 2, and 3 (11.1%) in Group 3 (overall p = 0.224, p = 0.11 between Group 2 and 3). Of those, 10 patients (1 (2.7%) in Group 1, 6 (19.4%) in Group 2, and 3 (11.1%) in Group 3) experienced a cardiac cause of death related to severe ADHF or cardiogenic shock.</p>
              </sec>
              <sec id="sec020">
                <title>KCCQ and PHQ-9 results</title>
                <p>A total of 77 (82%) patients had completed KCCQ data at baseline and 30-day follow-up. The median KCCQ overall summary score in all groups was 38.5 (IQR 24.2–53.7) at baseline, and 65.6 (IQR 43.8–81.3) at 30 days follow-up. From baseline to 30 days follow-up, 61 patients (80.3%) experienced a ≥5 point improvement in health status, while 5 patients (6.5%) experienced a ≥5 point decline. A higher proportion of patients who experienced ≥5 point improvement in KCCQ overall summary score were characterized as having NYHA class IV symptom limitations at baseline compared to those who reported a ≥5 point decline (57.6% vs. 40%, p = .004). There was a statistically significant change within groups with respect to KCCQ total symptom score, overall summary score, and clinical summary score however there were no significant between group differences (<bold><xref rid="pone.0253014.t003" ref-type="table">Table 3</xref></bold>).</p>
                <p>A total of 77 patients completed the baseline and 30 days follow-up PHQ-9 questionnaire. There was a statistically significant change within groups with respect to PHQ-9 total score. However, no significant changes were observed in between-group comparisons (<bold><xref rid="pone.0253014.t003" ref-type="table">Table 3</xref></bold>).</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="sec021">
              <title>Discussion</title>
              <p>In this randomized double blind placebo-controlled trial of 94 adult men and women following hospitalization for ADHF, we found that treatment following hospital discharge in an ambulatory diuretic infusion clinic with IV furosemide twice weekly for one month was associated with a significant reduction in the frequency of rehospitalization for ADHF at 30 days follow-up (3.7%) compared to placebo infusion and standard of care (22.6% and 17.1%, respectively). In addition, we found no documented adverse events with the use of IV diuretics. To our knowledge, our study is one of the first randomized controlled double blind studies evaluating the role of outpatient IV diuretic infusion clinics with a multidisciplinary approach to the treatment of HF to reduce 30 days re-admission for ADHF. Our overall rate of HF rehospitalization was reduced compared to the reported rates of 20–25% [<xref rid="pone.0253014.ref016" ref-type="bibr">16</xref>].</p>
              <p>We adopted the approach used in the Diuretic Optimization Strategies Evaluation (DOSE) trial and utilized a standardized furosemide infusion protocol which consisted of a furosemide bolus followed by a 3-hour infusion [<xref rid="pone.0253014.ref017" ref-type="bibr">17</xref>]. Our study showed as expected, a significant increase in urine output and weight loss in the IV furosemide group compared to the other two intervention groups. We found no significant differences in hemodynamic parameters including blood pressure or laboratory parameters in placebo versus furosemide infusion groups. Among patients receiving IV furosemide, patients with HFrEF experienced significant weight loss and increased urine output compared to those with HFpEF. Nonetheless the rate of worsening renal function (increased BUN or creatinine levels), were not different across both HF subtypes.</p>
              <p>Our results extend prior observational cohort studies evaluating the role of IV diuretics in ambulatory settings, supporting the reduction of HF re-hospitalization [<xref rid="pone.0253014.ref010" ref-type="bibr">10</xref>, <xref rid="pone.0253014.ref011" ref-type="bibr">11</xref>, <xref rid="pone.0253014.ref018" ref-type="bibr">18</xref>–<xref rid="pone.0253014.ref023" ref-type="bibr">23</xref>]. In a study of 60 chronic HF patients receiving outpatient IV furosemide bolus followed by 3-hour infusion, investigators found that infusions were associated with a median urine output of 1.1 L and 24 hours weight loss of 1.1 kg for the entire cohort including patients with HFrEF and HFpEF with an observed rate of all-cause hospitalization at 30 days of 31.7%, with no deaths.20 We report a similarly significant weight loss and urine output albeit not to the same degree. The differences may be due to heterogeneity of the baseline home diuretic dose (240mg daily furosemide home dose) compared to our study (70 mg daily furosemide home dose). Our study adds further to previous studies with the strength and uniqueness of its methodology as a randomized controlled trial, enrollment of both HFrEF and HFpEF patients, with a large representation of comorbidities, detailed monitoring of patients during infusions, and a longer duration of follow-up.</p>
              <p>Despite significant within group comparisons in KCCQ and PHQ-9 scores, we were not able to detect significant between-group changes. This may be due to the smaller proportion of patients experiencing a large magnitude of change in the questionnaire scores which may have limited the power to detect associations between improvements in the scores and outcome.</p>
              <p>This analysis has several limitations. Our study included a modest sample size from a single center. Notably, we recruited patients from a large urban center with a diverse population including 69% African Americans. Our analysis lacks reporting on hospital length of stay. Our study included unbalanced group sizes, which can be attributed to the differences in recruitment rate, a higher than expected loss to follow-up, time-research personnel logistics and budget constraints. However, the power of the study was maintained above 90% for both “per protocol” and “intension to treat” analyses. In our study design the standard of care group monitoring was solely an observatory arm and management was at the discretion of the HF specialty clinic. We acknowledge that some variations among cardiology practices between patient treatment and published evidence-based HF guidelines exist which may have influenced outcomes in the study. Given the large discrepancy in urine output between groups receiving placebo infusion (Group 2) and furosemide infusion (Group 3), it is possible that study personnel may have been able to determine randomization allocation, limiting blinding. Furthermore, a cost analysis of bi-weekly outpatient diuretic infusion is important however beyond the scope of the study design.</p>
              <p>Future clinical approaches to patient care are in line with evidence-based strategies utilizing a multidisciplinary care team in tailoring HF management. These evidence based strategies include the implementation of dedicated ambulatory outpatient monitoring clinics (including monitoring of hemodynamic data, weight, volume status, medication adherence, and salt intake) coupled with intervention (where IV diuretics are administered on an as-need basis). This approach may ultimately facilitate the decentralization of readmissions to hospitals, decreasing the healthcare cost burden and worsening outcomes in patients with ADHF.</p>
            </sec>
            <sec sec-type="conclusions" id="sec022">
              <title>Conclusions</title>
              <p>The ambulatory management of hemodynamically stable patients with ADHF, including those with HFrEF and HFpEF, utilizing a standardized protocol with IV diuretic treatment is feasible, safe, and effective in reducing 30 days re-hospitalization.</p>
            </sec>
            <sec id="sec023" sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="pone.0253014.s001" position="float" content-type="local-data">
                <label>S1 Fig</label>
                <caption>
                  <title>Baseline and follow-up echo images from patient in standard of care group.</title>
                  <p>Apical 4-Chamber View at Baseline (a) Parasternal Short Axis View at Baseline (b) Apical 4-Chamber View at Follow-up (c) Parasternal Short Axis View at Follow-up (d).</p>
                  <p>(TIFF)</p>
                </caption>
                <media xlink:href="pone.0253014.s001.tiff">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pone.0253014.s002" position="float" content-type="local-data">
                <label>S2 Fig</label>
                <caption>
                  <title>Pre- and post-infusion echo images from patient in IV placebo group.</title>
                  <p>Apical 4-Chamber View Pre-infusion (a) Parasternal Short Axis View Pre-infusion (b) Apical 4-Chamber View Post-infusion (c) Parasternal Short Axis View Post-infusion (d).</p>
                  <p>(TIFF)</p>
                </caption>
                <media xlink:href="pone.0253014.s002.tiff">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pone.0253014.s003" position="float" content-type="local-data">
                <label>S3 Fig</label>
                <caption>
                  <title>Pre- and post-infusion echo images from patient in IV furosemide group.</title>
                  <p>Apical 4-Chamber View Pre-infusion (a) Parasternal Short Axis View Pre-infusion (b) Apical 4-Chamber View Post-infusion (c) Parasternal Short Axis View Post-infusion (d).</p>
                  <p>(TIFF)</p>
                </caption>
                <media xlink:href="pone.0253014.s003.tiff">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pone.0253014.s004" position="float" content-type="local-data">
                <label>S1 Table</label>
                <caption>
                  <title>Baseline characteristics categorized by HF type.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0253014.s004.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pone.0253014.s005" position="float" content-type="local-data">
                <label>S2 Table</label>
                <caption>
                  <title>Infusion visit metrics changes (post infusion-pre infusion) categorized by intervention group and HF type.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0253014.s005.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pone.0253014.s006" position="float" content-type="local-data">
                <label>S3 Table</label>
                <caption>
                  <title>Changes in study outcome at 30 Days compared to baseline categorized by HF type.</title>
                  <p>(DOCX)</p>
                </caption>
                <media xlink:href="pone.0253014.s006.docx">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material id="pone.0253014.s007" position="float" content-type="local-data">
                <label>S1 File</label>
                <caption>
                  <title>OUTLAST study protocol.</title>
                  <p>(DOC)</p>
                </caption>
                <media xlink:href="pone.0253014.s007.doc">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ref-list>
              <title>References</title>
              <ref id="pone.0253014.ref001">
                <label>1</label>
                <mixed-citation publication-type="journal"><name><surname>Benjamin</surname><given-names>EJ</given-names></name>, <name><surname>Muntner</surname><given-names>P</given-names></name>, <name><surname>Alonso</surname><given-names>A</given-names></name>, <etal>et al</etal>. <article-title>Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association</article-title>. <source><italic toggle="yes">Circulation</italic></source>. <year>2019</year>;<volume>139</volume>(<issue>10</issue>):<fpage>e56</fpage>–<lpage>e528</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/CIR.0000000000000659</pub-id>
<?supplied-pmid 30700139?><pub-id pub-id-type="pmid">30700139</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref002">
                <label>2</label>
                <mixed-citation publication-type="journal"><name><surname>van Jaarsveld</surname><given-names>CH</given-names></name>, <name><surname>Ranchor</surname><given-names>AV</given-names></name>, <name><surname>Kempen</surname><given-names>GI</given-names></name>, <name><surname>Coyne</surname><given-names>JC</given-names></name>, <name><surname>van Veldhuisen</surname><given-names>DJ</given-names></name>, <name><surname>Sanderman</surname><given-names>R</given-names></name>. <article-title>Epidemiology of heart failure in a community-based study of subjects aged &gt; or = 57 years: incidence and long-term survival</article-title>. <source><italic toggle="yes">Eur J Heart Fail</italic></source>. <year>2006</year>;<volume>8</volume>(<issue>1</issue>):<fpage>23</fpage>–<lpage>30</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ejheart.2005.04.012</pub-id>
<?supplied-pmid 16209932?><pub-id pub-id-type="pmid">16209932</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref003">
                <label>3</label>
                <mixed-citation publication-type="journal"><name><surname>Rich</surname><given-names>MW</given-names></name>, <name><surname>Beckham</surname><given-names>V</given-names></name>, <name><surname>Wittenberg</surname><given-names>C</given-names></name>, <name><surname>Leven</surname><given-names>CL</given-names></name>, <name><surname>Freedland</surname><given-names>KE</given-names></name>, <name><surname>Carney</surname><given-names>RM</given-names></name>. <article-title>A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>1995</year>;<volume>333</volume>(<issue>18</issue>):<fpage>1190</fpage>–<lpage>1195</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJM199511023331806</pub-id>
<?supplied-pmid 7565975?><pub-id pub-id-type="pmid">7565975</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref004">
                <label>4</label>
                <mixed-citation publication-type="journal"><name><surname>Cline</surname><given-names>CM</given-names></name>, <name><surname>Israelsson</surname><given-names>BY</given-names></name>, <name><surname>Willenheimer</surname><given-names>RB</given-names></name>, <name><surname>Broms</surname><given-names>K</given-names></name>, <name><surname>Erhardt</surname><given-names>LR</given-names></name>. <article-title>Cost effective management programme for heart failure reduces hospitalisation</article-title>. <source><italic toggle="yes">Heart</italic></source>. <year>1998</year>;<volume>80</volume>(<issue>5</issue>):<fpage>442</fpage>–<lpage>446</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/hrt.80.5.442</pub-id>
<?supplied-pmid 9930041?><pub-id pub-id-type="pmid">9930041</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref005">
                <label>5</label>
                <mixed-citation publication-type="journal"><name><surname>Stewart</surname><given-names>S</given-names></name>, <name><surname>Marley</surname><given-names>JE</given-names></name>, <name><surname>Horowitz</surname><given-names>JD</given-names></name>. <article-title>Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study</article-title>. <source><italic toggle="yes">Lancet</italic></source>. <year>1999</year>;<volume>354</volume>(<issue>9184</issue>):<fpage>1077</fpage>–<lpage>1083</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0140-6736(99)03428-5</pub-id>
<?supplied-pmid 10509499?><pub-id pub-id-type="pmid">10509499</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref006">
                <label>6</label>
                <mixed-citation publication-type="journal"><name><surname>Blue</surname><given-names>L</given-names></name>, <name><surname>Lang</surname><given-names>E</given-names></name>, <name><surname>McMurray</surname><given-names>JJ</given-names></name>, <etal>et al</etal>. <article-title>Randomised controlled trial of specialist nurse intervention in heart failure</article-title>. <source><italic toggle="yes">Bmj</italic></source>. <year>2001</year>;<volume>323</volume>(<issue>7315</issue>):<fpage>715</fpage>–<lpage>718</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1136/bmj.323.7315.715</pub-id>
<?supplied-pmid 11576977?><pub-id pub-id-type="pmid">11576977</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref007">
                <label>7</label>
                <mixed-citation publication-type="journal"><name><surname>McDonald</surname><given-names>K</given-names></name>, <name><surname>Ledwidge</surname><given-names>M</given-names></name>, <name><surname>Cahill</surname><given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Heart failure management: multidisciplinary care has intrinsic benefit above the optimization of medical care</article-title>. <source><italic toggle="yes">J Card Fail</italic></source>. <year>2002</year>;<volume>8</volume>(<issue>3</issue>):<fpage>142</fpage>–<lpage>148</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1054/jcaf.2002.124340</pub-id>
<?supplied-pmid 12140806?><pub-id pub-id-type="pmid">12140806</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref008">
                <label>8</label>
                <mixed-citation publication-type="journal"><name><surname>Hauptman</surname><given-names>PJ</given-names></name>, <name><surname>Rich</surname><given-names>MW</given-names></name>, <name><surname>Heidenreich</surname><given-names>PA</given-names></name>, <etal>et al</etal>. <article-title>The heart failure clinic: a consensus statement of the Heart Failure Society of America</article-title>. <source><italic toggle="yes">J Card Fail</italic></source>. <year>2008</year>;<volume>14</volume>(<issue>10</issue>):<fpage>801</fpage>–<lpage>815</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cardfail.2008.10.005</pub-id>
<?supplied-pmid 19041043?><pub-id pub-id-type="pmid">19041043</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref009">
                <label>9</label>
                <mixed-citation publication-type="journal"><name><surname>Hamo</surname><given-names>CE</given-names></name>, <name><surname>O’Connor</surname><given-names>C</given-names></name>, <name><surname>Metra</surname><given-names>M</given-names></name>, <name><surname>Udelson</surname><given-names>JE</given-names></name>, <name><surname>Gheorghiade</surname><given-names>M</given-names></name>, <name><surname>Butler</surname><given-names>J</given-names></name>. <article-title>A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials</article-title>. <source><italic toggle="yes">J Card Fail</italic></source>. <year>2018</year>;<volume>24</volume>(<issue>11</issue>):<fpage>783</fpage>–<lpage>792</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.cardfail.2018.08.007</pub-id>
<?supplied-pmid 30217774?><pub-id pub-id-type="pmid">30217774</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref010">
                <label>10</label>
                <mixed-citation publication-type="journal"><name><surname>Ryder</surname><given-names>M</given-names></name>, <name><surname>Murphy</surname><given-names>NF</given-names></name>, <name><surname>McCaffrey</surname><given-names>D</given-names></name>, <name><surname>O’Loughlin</surname><given-names>C</given-names></name>, <name><surname>Ledwidge</surname><given-names>M</given-names></name>, <name><surname>McDonald</surname><given-names>K</given-names></name>. <article-title>Outpatient intravenous diuretic therapy; potential for marked reduction in hospitalisations for acute decompensated heart failure</article-title>. <source><italic toggle="yes">Eur J Heart Fail</italic></source>. <year>2008</year>;<volume>10</volume>(<issue>3</issue>):<fpage>267</fpage>–<lpage>272</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ejheart.2008.01.003</pub-id>
<?supplied-pmid 18308632?><pub-id pub-id-type="pmid">18308632</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref011">
                <label>11</label>
                <mixed-citation publication-type="journal"><name><surname>Hebert</surname><given-names>K</given-names></name>, <name><surname>Dias</surname><given-names>A</given-names></name>, <name><surname>Franco</surname><given-names>E</given-names></name>, <name><surname>Tamariz</surname><given-names>L</given-names></name>, <name><surname>Steen</surname><given-names>D</given-names></name>, <name><surname>Arcement</surname><given-names>LM</given-names></name>. <article-title>Open access to an outpatient intravenous diuresis program in a systolic heart failure disease management program</article-title>. <source><italic toggle="yes">Congest Heart Fail</italic></source>. <year>2011</year>;<volume>17</volume>(<issue>6</issue>):<fpage>309</fpage>–<lpage>313</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/j.1751-7133.2011.00224.x</pub-id>
<?supplied-pmid 22103923?><pub-id pub-id-type="pmid">22103923</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref012">
                <label>12</label>
                <mixed-citation publication-type="journal"><name><surname>Lang</surname><given-names>RM</given-names></name>, <name><surname>Badano</surname><given-names>LP</given-names></name>, <name><surname>Mor-Avi</surname><given-names>V</given-names></name>, <etal>et al</etal>. <article-title>Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging</article-title>. <source><italic toggle="yes">J Am Soc Echocardiogr</italic></source>. <year>2015</year>;<volume>28</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>39.e14</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.echo.2014.10.003</pub-id>
<?supplied-pmid 25559473?><pub-id pub-id-type="pmid">25559473</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref013">
                <label>13</label>
                <mixed-citation publication-type="journal"><name><surname>Green</surname><given-names>CP</given-names></name>, <name><surname>Porter</surname><given-names>CB</given-names></name>, <name><surname>Bresnahan</surname><given-names>DR</given-names></name>, <name><surname>Spertus</surname><given-names>JA</given-names></name>. <article-title>Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure</article-title>. <source><italic toggle="yes">J Am Coll Cardiol</italic></source>. <year>2000</year>;<volume>35</volume>(<issue>5</issue>):<fpage>1245</fpage>–<lpage>1255</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/s0735-1097(00)00531-3</pub-id>
<?supplied-pmid 10758967?><pub-id pub-id-type="pmid">10758967</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref014">
                <label>14</label>
                <mixed-citation publication-type="journal"><name><surname>Kroenke</surname><given-names>K</given-names></name>, <name><surname>Spitzer</surname><given-names>RL</given-names></name>, <name><surname>Williams</surname><given-names>JB</given-names></name>. <article-title>The PHQ-9: validity of a brief depression severity measure</article-title>. <source><italic toggle="yes">J Gen Intern Med</italic></source>. <year>2001</year>;<volume>16</volume>(<issue>9</issue>):<fpage>606</fpage>–<lpage>613</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1046/j.1525-1497.2001.016009606.x</pub-id>
<?supplied-pmid 11556941?><pub-id pub-id-type="pmid">11556941</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref015">
                <label>15</label>
                <mixed-citation publication-type="journal"><name><surname>Yancy</surname><given-names>CW</given-names></name>, <name><surname>Jessup</surname><given-names>M</given-names></name>, <name><surname>Bozkurt</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America</article-title>. <source><italic toggle="yes">Circulation</italic></source>. <year>2017</year>;<volume>136</volume>(<issue>6</issue>):<fpage>e137</fpage>–<lpage>e161</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/CIR.0000000000000509</pub-id>
<?supplied-pmid 28455343?><pub-id pub-id-type="pmid">28455343</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref016">
                <label>16</label>
                <mixed-citation publication-type="journal"><name><surname>Ross</surname><given-names>JS</given-names></name>, <name><surname>Chen</surname><given-names>J</given-names></name>, <name><surname>Lin</surname><given-names>Z</given-names></name>, <etal>et al</etal>. <article-title>Recent national trends in readmission rates after heart failure hospitalization</article-title>. <source><italic toggle="yes">Circ Heart Fail</italic></source>. <year>2010</year>;<volume>3</volume>(<issue>1</issue>):<fpage>97</fpage>–<lpage>103</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.109.885210</pub-id>
<?supplied-pmid 19903931?><pub-id pub-id-type="pmid">19903931</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref017">
                <label>17</label>
                <mixed-citation publication-type="journal"><name><surname>Felker</surname><given-names>GM</given-names></name>, <name><surname>Lee</surname><given-names>KL</given-names></name>, <name><surname>Bull</surname><given-names>DA</given-names></name>, <etal>et al</etal>. <article-title>Diuretic strategies in patients with acute decompensated heart failure</article-title>. <source><italic toggle="yes">N Engl J Med</italic></source>. <year>2011</year>;<volume>364</volume>(<issue>9</issue>):<fpage>797</fpage>–<lpage>805</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1056/NEJMoa1005419</pub-id>
<?supplied-pmid 21366472?><pub-id pub-id-type="pmid">21366472</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref018">
                <label>18</label>
                <mixed-citation publication-type="journal"><name><surname>Makadia</surname><given-names>S</given-names></name>, <name><surname>Simmons</surname><given-names>T</given-names></name>, <name><surname>Augustine</surname><given-names>S</given-names></name>, <etal>et al</etal>. <article-title>The diuresis clinic: a new paradigm for the treatment of mild decompensated heart failure</article-title>. <source><italic toggle="yes">Am J Med</italic></source>. <year>2015</year>;<volume>128</volume>(<issue>5</issue>):<fpage>527</fpage>–<lpage>531</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.amjmed.2014.11.028</pub-id>
<?supplied-pmid 25576670?><pub-id pub-id-type="pmid">25576670</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref019">
                <label>19</label>
                <mixed-citation publication-type="journal"><name><surname>Buckley</surname><given-names>LF</given-names></name>, <name><surname>Carter</surname><given-names>DM</given-names></name>, <name><surname>Matta</surname><given-names>L</given-names></name>, <etal>et al</etal>. <article-title>Intravenous Diuretic Therapy for the Management of Heart Failure and Volume Overload in a Multidisciplinary Outpatient Unit</article-title>. <source><italic toggle="yes">JACC Heart Fail</italic></source>. <year>2016</year>;<volume>4</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>8</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.jchf.2015.06.017</pub-id>
<?supplied-pmid 26656139?><pub-id pub-id-type="pmid">26656139</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref020">
                <label>20</label>
                <mixed-citation publication-type="journal"><name><surname>Banerjee</surname><given-names>P</given-names></name>, <name><surname>Tanner</surname><given-names>G</given-names></name>, <name><surname>Williams</surname><given-names>L</given-names></name>. <article-title>Intravenous diuretic day-care treatment for patients with heart failure</article-title>. <source>Clin Med (Lond)</source>. <year>2012</year>;<volume>12</volume>(<issue>2</issue>):<fpage>133</fpage>–<lpage>136</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.7861/clinmedicine.12-2-133</pub-id>
<?supplied-pmid 22586787?><pub-id pub-id-type="pmid">22586787</pub-id></mixed-citation>
              </ref>
              <ref id="pone.0253014.ref021">
                <label>21</label>
                <mixed-citation publication-type="journal"><name><surname>Roberts</surname><given-names>JD GA</given-names></name>, <name><surname>Makkar</surname><given-names>K</given-names></name>, <name><surname>Rathman</surname><given-names>L</given-names></name>. <article-title>Outpatient Diuretic Infusion Clinic: A Home for High Risk Heart Failure Patients</article-title>. <source><italic toggle="yes">J Card Fail</italic></source>. <year>2018</year><volume>24</volume>(<issue>8</issue>).</mixed-citation>
              </ref>
              <ref id="pone.0253014.ref022">
                <label>22</label>
                <mixed-citation publication-type="journal"><name><surname>Nyjo</surname><given-names>S</given-names></name>, <name><surname>Leigh</surname><given-names>J</given-names></name>, <name><surname>Jackson</surname><given-names>C</given-names></name>, <name><surname>Dubey</surname><given-names>G</given-names></name>, <name><surname>Sankaranarayanan</surname><given-names>R</given-names></name>, <name><surname>Douglas</surname><given-names>H</given-names></name>. <article-title>P1470Heart failure patients with high Charlson co-morbidity scores can be managed safely in a day-case ambulatory heart failure unit without the need for hospital admission</article-title>. <source><italic toggle="yes">European Heart Journal</italic></source>. <year>2017</year>;<volume>38</volume>(<issue>suppl_1</issue>).</mixed-citation>
              </ref>
              <ref id="pone.0253014.ref023">
                <label>23</label>
                <mixed-citation publication-type="journal"><name><surname>Schipper JE</surname><given-names>DG</given-names></name>, <name><surname>Dickson</surname><given-names>VV</given-names></name>, <name><surname>Katz</surname><given-names>SD</given-names></name>. <article-title>Implementation of tailored intravenous heart failure therapy in a non-dedicated outpatient infusion center</article-title>. <source><italic toggle="yes">J Card Fail</italic></source>. <year>2012</year>;<fpage>18</fpage>.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
